AbbVie’s Allergan Aesthetics wins EU approval for Boey frown-line treatment
ABBV•European Commission clears Boey for glabellar lines
AbbVie’s Allergan Aesthetics secured European Commission clearance for Boey (trenibotulinumtoxinE) to treat glabellar lines in adults.
The decision covers all 30 European Economic Area countries.
Boey is positioned as a rapid-onset, short-duration botulinum toxin, with effects seen in as little as 8 hours and lasting 2-3 weeks.
